PR Newswire Clinical TrialsOriginal article
ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients
Data Readout9MW1911Neutral
AI Analysis
Summary
Mabwell presented Phase Ib/IIa clinical results of anti-ST2 monoclonal antibody 9MW1911 in COPD patients at ERS 2026. The announcement provides early-stage clinical data on the investigational therapeutic.
Clinical Trial Data
Phase
Ib/IIa
Outcome Details
Phase Ib/IIa clinical results presented
Importance:5/10
Sentiment:
0.00
clinical_trialmonoclonal_antibodyCOPDdata_readoutconference
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 4, 2026 1:00 PM